Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$461M |
| 2 |
Qualcomm
QCOM
|
+$450M |
| 3 |
Marriott International
MAR
|
+$341M |
| 4 |
TIF
Tiffany & Co.
TIF
|
+$283M |
| 5 |
NRG Energy
NRG
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$962M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$551M |
| 3 |
WFM
Whole Foods Market Inc
WFM
|
+$510M |
| 4 |
Goldman Sachs
GS
|
+$478M |
| 5 |
Estee Lauder
EL
|
+$329M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.96% |
| 2 | Consumer Discretionary | 14.17% |
| 3 | Communication Services | 11.56% |
| 4 | Technology | 11.12% |
| 5 | Energy | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Webster Financial
WBS
$12.3B
| $5.3M | ﹤0.01% |
168,185
+22,158
| +15% | +$676K |
|
502
National Grid
NGG
$82.7B
| $5.21M | ﹤0.01% |
72,674
-512,466
| -88% | -$35.5M |
|
503
Akebia Therapeutics
AKBA
$327M
| $4.97M | ﹤0.01% |
+178,975
| New | +$4.31M |
|
|
TVRD
504
Tvardi Therapeutics
TVRD
$23.5M
| $4.86M | ﹤0.01% |
7,938
-1,906
| -19% | -$1.03M |
|
|
TRNX
505
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $4.79M | ﹤0.01% |
204,940
-33,772
| -14% | -$702K |
|
506
Brunswick
BC
$5.19B
| $4.68M | ﹤0.01% |
111,036
+26,357
| +31% | +$1.11M |
|
507
InspireMD
NSPR
$32M
| – | – |
0
| – | – |
|
|
TEN
508
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $4.28M | ﹤0.01% |
65,164
-5,345
| -8% | -$331K |
|
509
Intel
INTC
$466B
| $4.13M | ﹤0.01% |
133,674
+4,932
| +4% | +$135K |
|
510
Teekay
TK
$975M
| $4.12M | ﹤0.01% |
66,257
+61,496
| +1,292% | +$3.55M |
|
511
BioCryst Pharmaceuticals
BCRX
$2.37B
| $4.09M | ﹤0.01% |
320,942
-37,615
| -10% | -$366K |
|
512
Piper Sandler
PIPR
$5.14B
| $4.09M | ﹤0.01% |
316,152
+58,988
| +23% | +$664K |
|
513
RBC Bearings
RBC
$18.8B
| $4.08M | ﹤0.01% |
63,637
-285,334
| -82% | -$17.7M |
|
514
Verastem
VSTM
$532M
| $4.07M | ﹤0.01% |
37,397
-4,573
| -11% | -$497K |
|
515
Encompass Health
EHC
$11.2B
| $4.04M | ﹤0.01% |
141,744
+24,793
| +21% | +$691K |
|
516
Moog Inc Class A
MOG.A
$13B
| $4.03M | ﹤0.01% |
55,277
-5,630
| -9% | -$387K |
|
517
Chevron
CVX
$388B
| $4.01M | ﹤0.01% |
30,720
+3,923
| +15% | +$488K |
|
518
TG Therapeutics
TGTX
$8.58B
| $3.84M | ﹤0.01% |
408,797
-48,009
| -11% | -$307K |
|
|
AET
519
DELISTED
Aetna Inc
AET
| $3.83M | ﹤0.01% |
47,252
-54
| -0.1% | -$4.09K |
|
|
MGLN
520
DELISTED
Magellan Health Services, Inc.
MGLN
| $3.82M | ﹤0.01% |
61,308
-80
| -0.1% | -$4.7K |
|
521
Eli Lilly
LLY
$1.07T
| $3.81M | ﹤0.01% |
61,216
+11,206
| +22% | +$669K |
|
522
Johnson & Johnson
JNJ
$635B
| $3.78M | ﹤0.01% |
36,090
-2,978
| -8% | -$301K |
|
|
MRSH
523
Marsh
MRSH
$86.3B
| $3.67M | ﹤0.01% |
70,912
+53,624
| +310% | +$2.66M |
|
|
KRFT
524
DELISTED
KRAFT FOODS GROUP INC COM STK (VA)
KRFT
| $3.67M | ﹤0.01% |
61,213
+23,395
| +62% | +$1.35M |
|
525
DuPont de Nemours
DD
$18.6B
| $3.61M | ﹤0.01% |
27,703
-1,271
| -4% | -$162K |
|
Similar funds
Jennison Associates's Q2 2014 Portfolio in Review
As of Q2 2014, Jennison Associates held 796 positions worth $109B, up 4.1% from $105B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Jennison Associates's Q2 2014 filing shows 64 new, 297 increased, 319 reduced and 90 closed positions. Its largest new stake was Qualcomm: 5,657,444 shares worth $448M. The largest sale was Allergan Inc, an estimated $962M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q2 2014 buy was Qualcomm: 5,657,444 shares worth $448M.
- Jennison Associates added most to SLB Ltd in Q2 2014, an estimated $461M increase.
- Jennison Associates's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $962M.
- Jennison Associates fully exited Estee Lauder in Q2 2014, selling an estimated $329M.
- Jennison Associates's ten largest holdings make up 19% of its $109B portfolio in Q2 2014.
- Jennison Associates opened 64 new positions and closed 90 in Q2 2014.
- Jennison Associates's portfolio value rose 4.1% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2014, filed 8 Aug 2014.